Background: Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has also shown antiviral efficacy in antiretroviral-naive patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking.; Methods: HIV-1-infected patients with suppressed viral load (VL) during a PI-containing regimen (>12 months) and no previous virological failure were randomized to switch from the PI to ETR (400 mg/day, dissolved in water) (ETR group, n = 22) or to continue with the same regimen (control group, n = 21). Percentage of patients with VL 50 copies/mL); treatment was successful in 95.2% of the control group and 90.9% of the ETR group (intention-to-treat analysis, missing = fai...
Background: IEtravirine (ETR) was approved in France in Sept 2008, to be used in combination with a ...
Objective: This study investigates the effectiveness and tolerability of switching to darunavir/cobi...
Introduction: Switching to a rilpivirine, tenofovir and emtricitabine (RTE) single-tablet regimen (S...
Background: Etravirine (ETR) was approved for patients with virological failure and antiretroviral r...
Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mu...
Background: Etravirine (ETR) was approved for patients with virological failure and antiretroviral r...
BACKGROUND: Lifestyle changes and statins are the cornerstones in management of dyslipidaemia in pat...
BACKGROUND: Lifestyle changes and statins are the cornerstones in management of dyslipidaemia in pat...
Objective:To evaluate the efficacy and safety of switching from an abacavir/lamivudine (ABC/3TC)-bas...
Objective: To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125),...
Journal Article; ClinicalTrials.gov NCT01437241.Etravirine (ETV) is recommended in combination with ...
Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in ...
BACKGROUND:Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with in...
Background. Atazanavir is a once-daily protease inhibitor (PI) for the treatment of human immunodefi...
Objective: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritona...
Background: IEtravirine (ETR) was approved in France in Sept 2008, to be used in combination with a ...
Objective: This study investigates the effectiveness and tolerability of switching to darunavir/cobi...
Introduction: Switching to a rilpivirine, tenofovir and emtricitabine (RTE) single-tablet regimen (S...
Background: Etravirine (ETR) was approved for patients with virological failure and antiretroviral r...
Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mu...
Background: Etravirine (ETR) was approved for patients with virological failure and antiretroviral r...
BACKGROUND: Lifestyle changes and statins are the cornerstones in management of dyslipidaemia in pat...
BACKGROUND: Lifestyle changes and statins are the cornerstones in management of dyslipidaemia in pat...
Objective:To evaluate the efficacy and safety of switching from an abacavir/lamivudine (ABC/3TC)-bas...
Objective: To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125),...
Journal Article; ClinicalTrials.gov NCT01437241.Etravirine (ETV) is recommended in combination with ...
Unlike other nonnucleoside reverse transcriptase inhibitors, etravirine is only approved for use in ...
BACKGROUND:Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with in...
Background. Atazanavir is a once-daily protease inhibitor (PI) for the treatment of human immunodefi...
Objective: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritona...
Background: IEtravirine (ETR) was approved in France in Sept 2008, to be used in combination with a ...
Objective: This study investigates the effectiveness and tolerability of switching to darunavir/cobi...
Introduction: Switching to a rilpivirine, tenofovir and emtricitabine (RTE) single-tablet regimen (S...